Akèy › Leksemi biphenotipik egi › Iowa
Etid klinik pou Leksemi biphenotipik egi nan Iowa
4 etid pou Leksemi biphenotipik egi ap chèche patisipan nan sit nan Iowa.
Vil nan Iowa
Tèks ofisyèl etid la (Anglè)
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Blank Children's Hospital, Des Moines
Ap rekriteFaz 2
365 Days · Tout sèks · Mizajou Sep 25, 2026 · NCT06317662A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- University of Iowa Hospital, Iowa City
Ap rekriteFaz 1/2
30 Days · Tout sèks · Mizajou Sep 16, 2026 · NCT04065399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Blank Children's Hospital, Des Moines
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
Ap rekriteFaz 3
365 Days – 25 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Blank Children's Hospital, Des Moines
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
Ap rekriteFaz 1/2
Jiska laj 22 · Tout sèks · Mizajou Aug 25, 2026 · NCT04726241Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.